August 24, 2025
2 min watch
LONG BEACH, Calif. — More than 70% of patients in a phase 2 study achieved 24 weeks without a supplemental injection when treated with a high dose of EYP-1901, an intravitreal insert designed to deliver vorolanib for diabetic macular edema.
Results from the phase 2 VERONA study show promising durability for the sustained-release therapy.
- EYP-1901, an intravitreal insert for diabetic macular edema, met its primary endpoint in the phase 2 VERONA study.
- Over 70% of patients receiving high-dose EYP-1901 reached 24 weeks without needing a supplemental injection.
- About one-third of patients still require repeat treatment.
- Monthly monitoring may be needed for patients with suboptimal responses.
Yasha S. Modi, MD, of NYU Langone Health, discussed these end-of-study results for EYP-1901 from EyePoint Pharmaceuticals at the American Society of Retina Specialists annual meeting. The therapy is a bioerodible, sustained-release intravitreal insert for diabetic macular edema.
Despite the positive results, Modi noted that approximately one-third of patients still require repeat treatment. “So, we will have to follow these patients on a monthly basis in the clinical trial and will then have to devise a system to be able to ensure that they are getting supplements when they need them if they were to have a suboptimal response to tyrosine kinase inhibitors,” she said.
